BeOne Medicines (ONC) Q4 2024 earnings summary

Executive summary

• Achieved $3.8B in 2024 revenue, with $1.1B in Q4, driven by BRUKINSA's U.S. leadership and global expansion, and positive cash flow from operations in Q3 and Q4.

• BRUKINSA became the #1 BTK inhibitor in the U.S. for new CLL patient starts and value share, with U.S. sales leading growth.

• Advanced 13 new molecular entities into the clinic and completed an $800M U.S. manufacturing facility.

• Announced intent to change company name to BeOne Medicines Ltd. and re-domicile to Switzerland.

• Focus for 2025 includes deepening hematology leadership, advancing the pipeline, and driving superior financial performance.

Financial highlights

• FY2024 revenue rose 55% year-over-year to $3.8B; Q4 revenue reached $1.1B, up 78% from Q4 2023.

• BRUKINSA revenue doubled to $2.64B in FY2024, with Q4 sales at $828M, up 100% year-over-year.

• Gross margin improved to 85.6% in Q4 and 84.3% for FY2024 (GAAP), with adjusted gross margin at 87.4% in Q4.

• Non-GAAP operating income reached $79M in Q4 and $45M for FY2024, with three consecutive quarters of positive non-GAAP operating income.

• Cash position at year-end was $2.6B, with positive cash flow from operations in Q3 and Q4.

Outlook and guidance

• FY2025 revenue guidance is $4.9B–$5.3B, assuming stable U.S. net pricing and continued global expansion.

• GAAP gross margin expected in the mid-80% range; operating expenses forecast at $4.1B–$4.4B.

• Affirmed commitment to full-year GAAP operating breakeven and positive cash flow from operations in 2025.

• Guidance assumes no new material business development or non-recurring items.

• U.S. BRUKINSA expected to gain further new patient share, with growth from Europe and new launches in Japan.